A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Active:	No
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT03861793
Trial Phases:	Phase I Phase II	Protocol IDs:	ALKS 4230-001 (primary) NCI-2019-02348
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Mural Oncology, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT03861793

Summary

This study will characterize the safety and tolerability and identify the recommended Phase 2
dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with
pembrolizumab.

Objectives

This study will evaluate ALKS 4230 administered SC as lead-in monotherapy and in combination
with pembrolizumab in subjects with advanced solid tumors.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.